BBH offers concentrated exposure to biotech, while IHE provides higher income with lower volatility by focusing on ...

The Fund seeks to track the investment results of the Dow Jones US Select Pharmaceuticals Index composed of US equities in the pharmaceuticals sector. The Fund invests at least 90% of its assets in ...

IHE delivered stronger 5-year returns, but VHT's 0.09% expense ratio and 411 holdings offer broader diversification at lower ...

The iShares Global Healthcare ETF offers greater diversification across geography and industries. Two of its top ten holdings don’t sell pharmaceuticals. Plus, its second-largest holding, Johnson & ...

The iShares U.S. Pharmaceuticals ETF (NYSEMKT:IHE) offers lower fees and a higher dividend yield, while the Invesco Pharmaceuticals ETF (NYSEMKT:PJP) spreads its holdings more evenly across the sector ...

Looking for broad exposure to the Healthcare - Pharma segment of the equity market? You should consider the iShares U.S. Pharmaceuticals ETF (IHE), a passively managed exchange traded fund launched on ...

Established pharmaceutical giants have delivered lower volatility and higher income than clinical-stage biotech exposure over the past five years.

iShares U.S. Pharmaceuticals ETF (IHE) has 46.8% of its $1.1B portfolio concentrated in Johnson & Johnson (JNJ), up 14% year-to-date on strong DARZALEX sales of $3.90B, and Eli Lilly (LLY), down 15% ...

iShares U.S. Pharmaceuticals ETF provides concentrated exposure domestic drug manufacturers while iShares Global Healthcare ETF holds more than 100 companies across the global healthcare sector.

The iShares U.S. Pharmaceuticals ETF (IHE) charges a lower expense ratio and pays a higher dividend than the Invesco Pharmaceuticals ETF (PJP). IHE is heavily concentrated in its two largest holdings, ...